Matches in DBpedia 2016-04 for { ?s ?p "Brett P. Giroir, M.D. (born November 4, 1960 in Marrero, Louisiana) is an internationally recognized expert in life science strategy and innovation and founding CEO of Health Science and Biosecurity Partners, LLC. He has led major initiatives for academic institutions, the U.S. Departments of Defense and Health and Human Services, global corporations, and new life science ventures. Dr. Giroir currently serves as Senior Fellow at the Texas Medical Center Health Policy Institute and Strategic Advisor for the Texas Medical Center Innovation Institute (TMCx). He is a member of the Texas Task Force for Infectious Disease Preparedness and Response (charted initially by the Governor to respond to Texas Ebola cases), Special Advisor to the President of the University of North Texas Health Science Center, and Adjunct Professor of Pediatrics and Tropical Medicine at the Baylor College of Medicine.Most recently, Dr. Giroir chaired the independent Blue Ribbon Panel for the Veterans Choice and Accountability Act of 2014, whose comprehensive assessment and recommendations to reform the Veterans Administration Health System were delivered to Congress and Secretary Robert McDonald on September 1, 2015. Dr. Giroir subsequently testified to the full House Committee on Veterans Affairs on October 7, 2015, and communicated priorities for VA reform in the New England Journal of Medicine.Dr. Giroir served as the Deputy Director, then Director, of DARPA’s Defense Science Office from 2004 to 2008, Vice Chancellor for the Texas A&M University System from 2008 to 2013, and as Chief Executive Officer of the Texas A&M Health Science Center from 2013 to 2015. He is widely known for leading novel biomedical initiatives within Texas culminating in the 2012 announcement of a public private partnership with the U.S. Department of Health and Human Service Biomedical Research and Development Authority to accelerate development and manufacturing of vaccines and therapeutics for pandemic influenza and emerging infectious diseases. This partnership had a $3 billion contract value over 25 years, with an estimated $41 billion in economic impact to Texas."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Brett_Giroir abstract "Brett P. Giroir, M.D. (born November 4, 1960 in Marrero, Louisiana) is an internationally recognized expert in life science strategy and innovation and founding CEO of Health Science and Biosecurity Partners, LLC. He has led major initiatives for academic institutions, the U.S. Departments of Defense and Health and Human Services, global corporations, and new life science ventures. Dr. Giroir currently serves as Senior Fellow at the Texas Medical Center Health Policy Institute and Strategic Advisor for the Texas Medical Center Innovation Institute (TMCx). He is a member of the Texas Task Force for Infectious Disease Preparedness and Response (charted initially by the Governor to respond to Texas Ebola cases), Special Advisor to the President of the University of North Texas Health Science Center, and Adjunct Professor of Pediatrics and Tropical Medicine at the Baylor College of Medicine.Most recently, Dr. Giroir chaired the independent Blue Ribbon Panel for the Veterans Choice and Accountability Act of 2014, whose comprehensive assessment and recommendations to reform the Veterans Administration Health System were delivered to Congress and Secretary Robert McDonald on September 1, 2015. Dr. Giroir subsequently testified to the full House Committee on Veterans Affairs on October 7, 2015, and communicated priorities for VA reform in the New England Journal of Medicine.Dr. Giroir served as the Deputy Director, then Director, of DARPA’s Defense Science Office from 2004 to 2008, Vice Chancellor for the Texas A&M University System from 2008 to 2013, and as Chief Executive Officer of the Texas A&M Health Science Center from 2013 to 2015. He is widely known for leading novel biomedical initiatives within Texas culminating in the 2012 announcement of a public private partnership with the U.S. Department of Health and Human Service Biomedical Research and Development Authority to accelerate development and manufacturing of vaccines and therapeutics for pandemic influenza and emerging infectious diseases. This partnership had a $3 billion contract value over 25 years, with an estimated $41 billion in economic impact to Texas.".
- Q4962188 abstract "Brett P. Giroir, M.D. (born November 4, 1960 in Marrero, Louisiana) is an internationally recognized expert in life science strategy and innovation and founding CEO of Health Science and Biosecurity Partners, LLC. He has led major initiatives for academic institutions, the U.S. Departments of Defense and Health and Human Services, global corporations, and new life science ventures. Dr. Giroir currently serves as Senior Fellow at the Texas Medical Center Health Policy Institute and Strategic Advisor for the Texas Medical Center Innovation Institute (TMCx). He is a member of the Texas Task Force for Infectious Disease Preparedness and Response (charted initially by the Governor to respond to Texas Ebola cases), Special Advisor to the President of the University of North Texas Health Science Center, and Adjunct Professor of Pediatrics and Tropical Medicine at the Baylor College of Medicine.Most recently, Dr. Giroir chaired the independent Blue Ribbon Panel for the Veterans Choice and Accountability Act of 2014, whose comprehensive assessment and recommendations to reform the Veterans Administration Health System were delivered to Congress and Secretary Robert McDonald on September 1, 2015. Dr. Giroir subsequently testified to the full House Committee on Veterans Affairs on October 7, 2015, and communicated priorities for VA reform in the New England Journal of Medicine.Dr. Giroir served as the Deputy Director, then Director, of DARPA’s Defense Science Office from 2004 to 2008, Vice Chancellor for the Texas A&M University System from 2008 to 2013, and as Chief Executive Officer of the Texas A&M Health Science Center from 2013 to 2015. He is widely known for leading novel biomedical initiatives within Texas culminating in the 2012 announcement of a public private partnership with the U.S. Department of Health and Human Service Biomedical Research and Development Authority to accelerate development and manufacturing of vaccines and therapeutics for pandemic influenza and emerging infectious diseases. This partnership had a $3 billion contract value over 25 years, with an estimated $41 billion in economic impact to Texas.".